Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2023

In 2023, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 4.77% of shares outstanding on 13 Jan 2023 to 5.17% on 29 Dec 2023, a change of +0.40 percentage points. The year's high was 5.33% on 15 Nov 2023 and its low 4.52% on 14 Apr 2023, averaging 4.88% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.44 days on 30 Nov 2023. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2023

2023 in figures

Start of year
4.77% (13 Jan 2023)
End of year
5.17% (29 Dec 2023)
Change
+0.40 pp
High
5.33% (15 Nov 2023)
Low
4.52% (14 Apr 2023)
Average
4.88%
Highest days to cover
12.44 (30 Nov 2023)
SEC filings marked
8

Every report in 2023

LIGAND PHARMACEUTICALS INC short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.77%7.35
31 Jan 20234.77%8.01
15 Feb 20234.84%7.91
28 Feb 20234.91%5.37results (8-K), 10-K filed
15 Mar 20235.27%7.25
31 Mar 20234.56%5.56
14 Apr 20234.52%8.51
28 Apr 20234.75%9.32
15 May 20234.73%9.35results (8-K), 10-Q filed
31 May 20234.79%8.10
15 Jun 20234.71%7.66
30 Jun 20234.90%6.97
14 Jul 20234.83%9.50
31 Jul 20234.67%10.16
15 Aug 20234.84%8.65results (8-K), 10-Q filed
31 Aug 20235.07%9.92
15 Sep 20234.75%6.53
29 Sep 20234.75%7.88
13 Oct 20234.87%10.45
31 Oct 20235.05%9.93
15 Nov 20235.33%7.73results (8-K), 10-Q filed
30 Nov 20235.21%12.44
15 Dec 20235.12%5.55
29 Dec 20235.17%8.28

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.